Nasdaq site scans 13-F SEC filings from major institutions. That has nothing to do with individual clients. Blackrock added 85 new positions last quarter. We were one of those. What we also know is was added sometime during Q2 and was still held as of the end of June. Same with Vanguard and others. Some seem to think Bryostatin showed enough from the 2B trial to warrant a speculative investment. That much is obvious.
News 
Market Data 
Discover 
